安旭生物(688075)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
暂无数据
  盈利预测
据安旭生物三季报分析:

  盈利能力明显恶化,总资产收益能力急剧下降

  成长能力明显恶化,经营业绩承受明显压力

  偿债能力有所加强,偿还流动负债能力很强

  运营能力明显恶化,产品市场竞争力明显减弱

  现金流能力明显恶化,销售回款能力短期内恶化

  财务数据
    截至第三季度实现净利润1.86亿元,每股收益1.47元。

    截至第三季度最新股东权益515197.30万元,未分配利润392333.14万元。

    截至第三季度最新总资产588188.35万元,负债72991.05万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入316,140,350.49204,374,691.1121,477,537.336,165,884,330.92
营业总成本215,762,189.9998,764,549.95115,414,863.111,967,504,281.97
营业利润211,124,693.33187,697,400.0356,026,055.473,528,837,110.45
利润总额206,601,823.45188,193,859.9356,031,344.483,519,508,115.64
净利润186,362,914.02166,501,431.950,378,384.593,044,171,657.91
其他综合收益705,904.12709,039.658,357,524.98,738,843.3
综合收益总额187,068,818.14167,210,471.5658,735,909.493,052,910,501.21
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计4,939,056,218.35,326,362,524.346,248,634,020.116,206,106,624.28
非流动资产合计942,827,276.28932,818,396.33694,429,560.6735,575,582.05
资产总计5,881,883,494.586,259,180,920.676,943,063,580.716,941,682,206.33
流动负债合计572,474,255.76966,545,291.841,293,104,674.321,358,293,896.23
非流动负债合计157,436,238.53160,520,975.12158,610,447.49164,616,967.94
负债合计729,910,494.291,127,066,266.961,451,715,121.81,522,910,864.17
归属于母公司股东权益合计5,155,614,554.525,135,553,068.325,494,966,329.245,421,936,037.32
股东权益合计5,151,973,000.295,132,114,653.715,491,348,458.95,418,771,342.16
负债和股东权益合计5,881,883,494.586,259,180,920.676,943,063,580.716,941,682,206.33
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计565,921,380.07427,533,342.71306,265,340.176,907,750,653.25
经营活动现金流出小计1,250,308,486.271,114,871,378.86426,263,185.413,164,472,581.63
经营活动产生的现金流量净额-684,387,106.2-687,338,036.15-119,997,845.243,743,278,071.62
投资活动现金流入小计8,153,744,355.185,389,493,858.453,441,647,758.176,805,168,971.28
投资活动现金流出小计8,468,341,778.716,040,710,707.594,661,154,193.8110,419,460,724.6
投资活动产生的现金流量净额-314,597,423.53-651,216,849.14-1,219,506,435.64-3,614,291,753.32
筹资活动现金流入小计--4,874.39-
筹资活动现金流出小计436,308,925.7113,497,393.716,380.55253,296,474.42
筹资活动产生的现金流量净额-436,308,925.7-113,497,393.7-11,506.16-253,296,474.42
汇率变动对现金及现金等价物的影响21,423,411.7214,441,167.21-4,119,102.21215,233,596.99
现金及现金等价物净增加额-1,413,870,043.71-1,437,611,111.78-1,343,634,889.2590,923,440.87
期末现金及现金等价物余额724,290,399.91700,521,706.61794,525,554.372,138,132,818.39
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润1.86亿元,每股收益1.47元。

    截至第三季度最新股东权益515197.30万元,未分配利润392333.14万元。

    截至第三季度最新总资产588188.35万元,负债72991.05万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入316,140,350.49204,374,691.1121,477,537.336,165,884,330.92
营业总成本215,762,189.9998,764,549.95115,414,863.111,967,504,281.97
营业利润211,124,693.33187,697,400.0356,026,055.473,528,837,110.45
利润总额206,601,823.45188,193,859.9356,031,344.483,519,508,115.64
净利润186,362,914.02166,501,431.950,378,384.593,044,171,657.91
其他综合收益705,904.12709,039.658,357,524.98,738,843.3
综合收益总额187,068,818.14167,210,471.5658,735,909.493,052,910,501.21
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计4,939,056,218.35,326,362,524.346,248,634,020.116,206,106,624.28
非流动资产合计942,827,276.28932,818,396.33694,429,560.6735,575,582.05
资产总计5,881,883,494.586,259,180,920.676,943,063,580.716,941,682,206.33
流动负债合计572,474,255.76966,545,291.841,293,104,674.321,358,293,896.23
非流动负债合计157,436,238.53160,520,975.12158,610,447.49164,616,967.94
负债合计729,910,494.291,127,066,266.961,451,715,121.81,522,910,864.17
归属于母公司股东权益合计5,155,614,554.525,135,553,068.325,494,966,329.245,421,936,037.32
股东权益合计5,151,973,000.295,132,114,653.715,491,348,458.95,418,771,342.16
负债和股东权益合计5,881,883,494.586,259,180,920.676,943,063,580.716,941,682,206.33
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计565,921,380.07427,533,342.71306,265,340.176,907,750,653.25
经营活动现金流出小计1,250,308,486.271,114,871,378.86426,263,185.413,164,472,581.63
经营活动产生的现金流量净额-684,387,106.2-687,338,036.15-119,997,845.243,743,278,071.62
投资活动现金流入小计8,153,744,355.185,389,493,858.453,441,647,758.176,805,168,971.28
投资活动现金流出小计8,468,341,778.716,040,710,707.594,661,154,193.8110,419,460,724.6
投资活动产生的现金流量净额-314,597,423.53-651,216,849.14-1,219,506,435.64-3,614,291,753.32
筹资活动现金流入小计--4,874.39-
筹资活动现金流出小计436,308,925.7113,497,393.716,380.55253,296,474.42
筹资活动产生的现金流量净额-436,308,925.7-113,497,393.7-11,506.16-253,296,474.42
汇率变动对现金及现金等价物的影响21,423,411.7214,441,167.21-4,119,102.21215,233,596.99
现金及现金等价物净增加额-1,413,870,043.71-1,437,611,111.78-1,343,634,889.2590,923,440.87
期末现金及现金等价物余额724,290,399.91700,521,706.61794,525,554.372,138,132,818.39
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
成都勤学善思教育科技有限公司119.833.9225.54
张彬30.190.994.87
中国银行股份有限公司-华泰柏瑞质量领先混合型证券投资基金27.210.8927.21
国泰基金-交通银行-国泰基金博远20号集合资产管理计划26.600.8726.60
香港中央结算有限公司25.520.837.36
陈伟平23.350.761.93
国泰基金-上海银行-国泰基金格物2号集合资产管理计划22.670.7422.67
许道意15.340.500.00
肖桂香12.730.420.00
陈志忠12.500.410.00
  主力控盘
  公司简介
安旭生物 所属地域: 浙江省 涉及概念: 沪股通,抗原检测,猴痘概念,新冠检测,融资融券
主营业务: 制造、加工:非医疗用生物材料及农产品的检测产品,第一、第二、第三类医疗器械;批发、零售:第一、二、三类医疗器械,医药中间体;服务:生物制品技术、计算机软件的技术开发、成果转让、技术咨询、技术服务,货物进出口(法律法规禁止的项目除外,国家法律、法规限制的项目取得许可证后方可经营)。(依法须经批准的项目,经相关部门批准后方可开展经营活动)
上市日期: 2021-11-18 每股净资产: 40.57元 每股收益: 1.47元 净利润: 1.87亿元 净利润增长率: -94.03%
营业收入: 3.16亿元 每股现金流: -5.39元 每股公积金: 8.27元 每股未分配利润: 30.87元 总股本: 1.27亿 流通股: 0.32亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心